GlassScriptPhysician profile
Marco A Ayulo
NPI 1316938848
$4,477.55
in general payments reported to CMS, 2019-2025
41 companies · $952 in 2025
The $952 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $83.77 · 2021: $1,291 · 2022: $497 · 2023: $677 · 2024: $777 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Long Term Medical Supply Or Device Loan: $250 · Education: $90.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.12 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $90.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,880.66 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $192.26 | 2020-2025 | Calquence, Lynparza |
| Astellas Pharma US INC | $186.71 | 2025 | Vyloy |
| Merck Sharp & Dohme LLC | $178.78 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $166.51 | 2023-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $163.62 | 2022-2025 | |
| Daiichi Sankyo INC. | $144.49 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Stemline Therapeutics INC. | $122.65 | 2023-2024 | Orserdu, Elzonris |
| Celgene Corporation | $114.09 | 2022-2025 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.01 | 2019-2022 | |
| Lilly USA, LLC | $95.37 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $87.49 | 2019 | |
| Janssen Biotech, INC. | $85.20 | 2021-2025 | Rybrevant, Tecvayli, Darzalex |
| Beigene USA, INC. | $66.82 | 2023-2024 | Brukinsa |
| Puma Biotechnology, INC. | $66.16 | 2023-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Ayulo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.